Fecha de publicación: -- Fuente: WIPO "tomato" The disclosure describes engineering of lymphocytes, particularly chimeric antigen receptor (CAR) T cells, to improve their action as therapeutic in treating cancer, such as by improving lymphocyte persistence and expansion. In particular, the disclosure provides lymphocytes with reduced or eliminated SAGA complex function, including ATXNL3 and/or USP22 expression, optionally co-administered with CD4+ cells as a source of companion IL-2 production.